Profound Medical Corp. PROF · Stock Open Profound Medical Corp. in new tab
Profound Medical Corp. Analysis (PROF)
Is Profound Medical Corp. a good investment? Profound Medical Corp. (PROF) is currently trading at 8.27 USD. Market analysts have a consensus price target of 11.14 USD. This suggests a potential upside from current levels.
Earnings Schedule: Profound Medical Corp. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.75.
Investor FAQ
Does Profound Medical Corp. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Profound Medical Corp.?
Profound Medical Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.24.
Company Profile
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 16, 2019 | 0.100000 |
Community Discussion